Orchestra BioMed

Update in progress

OBIO (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Orchestra BioMed Holdings, Inc. is a U.S. biomedical company focused on cardiovascular therapies and related devices. Lead programs include AVIM, a bioelectronic therapy aimed at quickly and durably lowering blood pressure; Virtue Sirolimus AngioInfusion Balloon for atherosclerotic disease; Cardiac Neuromodulation Therapy and CNT-HF for heart failure; and FreeHold and Pure-Vu systems for minimally invasive care. It collaborates with Medtronic on AVIM and with Terumo on Virtue SAB. Founded 2018, based in New Hope, PA.

Company score

Sentiment: 0.38; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.24; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.11; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.09; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.24; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive